Randomized controlled trial of two intravenous doses of granisetron (1mg vs 3mg) for the prophylaxis of chemotherapy-induced nausea and vomiting in cancer patients

Randomized controlled trial of two intravenous doses of granisetron (1mg vs 3mg) for the prophylaxis of chemotherapy-induced nausea and vomiting in cancer patients - Randomized controlled trial of granisetron for the prophylaxis of chemotherapy-induced nausea and vomiting

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000304

Enrollment

180

Registered

2006-01-11

Start date

2006-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer , ovarian cancer , cervical cancer , endometrial cancer , etc

Interventions

Granisetron 1mg/body (drip on intravenous,day1) Granisetron 3mg/body (drip on intravenous,day1)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)20 years-old over (2)PS (Eastern Cooperative Oncology Group performance status scale) 0-2 (3)patients to use the neoplastic agents belong to the acute emetic High risk category <refer to the ASCO clinical practice guideline,Recommendations for the use of Antiemetics> (4)Each of the following values are examined within 3weeks before registration for this study 1)ANC>=1,000/mm2 2)GPT(ALT) <100IU/L 3)CRE<=1.5 (CBDCA:CRE<=2.5) (5)Written informed consent

Exclusion criteria

Exclusion criteria: (1)patients with known hypersensitivity to 5-HT3 receptor antagonist (2)patients to use the neoplastic agents belong to the acute emetic category intermediate and High risk or to do the radiation therapy between Day2 and 7 (3)serious complications excepting malignancy (e.g. bowel obdormition, fibroid lung, cerebrovascular accident, active gastric and duodenum) (4)can't exactly record episodes in diaries, Shoujyou-nisshi

Design outcomes

Primary

Measure	Time frame
Complete Response	—

Secondary

Measure	Time frame
Complete control	—

Countries

Japan

Contacts

Public ContactMasahito Yonemura

Granisetorn coordinating office Pharmacy Division of National Cancer Center Hospital

myonemur@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026